<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336659</url>
  </required_header>
  <id_info>
    <org_study_id>MSV-14</org_study_id>
    <nct_id>NCT02336659</nct_id>
  </id_info>
  <brief_title>Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery</brief_title>
  <official_title>Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effect of GLP-1 and other gut-secreted hormones
      (glucagon, GIP, grelin and PYY) on food-intake, appetite and glucose metabolism after
      Roux-en-Y gastric bypass surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To do this the effect of combined GLP-1 receptor blockade by Exendin 9-39 and
      DPP-4-inhibition will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum food intake (changes in food intake)</measure>
    <time_frame>3-12 month after RYGB</time_frame>
    <description>Evaluated by changes in food intake between the placebo day and the day with both administration of exendin 9-39 and DPP 4 Inhibitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism (iAUC of glucose and c-pep after a meal)</measure>
    <time_frame>3-12 month after RYGB</time_frame>
    <description>Evaluated by iAUC of glucose and c-pep after a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut-derived hormone profiles (iAUC of GLP-1, PYY, GIP and glucagon after a meal)</measure>
    <time_frame>3-12 month after RYGB</time_frame>
    <description>Evaluated by iAUC of GLP-1, PYY, GIP and glucagon after a meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite measurement (VAS-scores)</measure>
    <time_frame>3-12 month after RYGB</time_frame>
    <description>Evaluated by VAS-scores</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Severe Obesity</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mixed meal test and ad libitum meal test duing infusion of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin 9-39</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4 Inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin 9-39 / DPP 4-Inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin 9-39</intervention_name>
    <description>Exendin 9-39 is a specific GLP-1 receptor antagonist</description>
    <arm_group_label>Exendin 9-39</arm_group_label>
    <arm_group_label>Exendin 9-39 / DPP 4-Inhibition</arm_group_label>
    <other_name>GLP-1 antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>DPP-4 Inhibition</description>
    <arm_group_label>DPP-4 Inhibition</arm_group_label>
    <arm_group_label>Exendin 9-39 / DPP 4-Inhibition</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncomplicated RYGB performed 3-12 month proir to the study. Fasting plasma glucose
             &lt;7.0 mM and HbA1c &lt; 48 mmol/mol 3 month after RYGB.

        Exclusion Criteria:

          -  Fasting plasma glucose &gt;7.0 mM and HbA1c &gt; 48 mmol/mol 3 month after RYGB. Hemoglobin
             &lt;6.5mM. Previous anaphylaxis when treated with Januvia or Byetta. Allergy for
             sitagliptin. Dysregulated hypothyroidism. Use of antithyroid treatment. Late diabetic
             complications as retinopathy, renal insuffiency, neuropathy or previous pancreatitis.
             Bad compliance.

          -  Complications to RYGB: Documented reactive hypoglycaemia, severe dumping (with
             vomiting, diarrhea or severe abdominal pain after food intake).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sten Madbad, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Saur Svane</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

